Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's Gamma Brachytherapy System Effectively Reduces Restenosis - TCT

This article was originally published in The Gray Sheet

Executive Summary

Physicians treating in-stent restenosis with intravascular brachytherapy should avoid placing new stents at the time of radiation, Paul Teirstein, MD, Scripps Clinic, La Jolla, California cautioned in a Sept. 23 release announcing the results of the Johnson & Johnson GAMMA I trial.

You may also be interested in...



Implant Sciences System Could Address Gamma Radiation Safety Concerns

Implant Sciences feels its "soft" gamma ray-emitting system for the prevention of restenosis following coronary angioplasty is capable of overcoming hospital personnel safety concerns associated with similar brachytherapy systems.

Implant Sciences System Could Address Gamma Radiation Safety Concerns

Implant Sciences feels its "soft" gamma ray-emitting system for the prevention of restenosis following coronary angioplasty is capable of overcoming hospital personnel safety concerns associated with similar brachytherapy systems.

CDRH Guardedly Optimistic About Brachytherapy For In-Stent Restenosis

FDA Center for Devices and Radiological Health Director David Feigal praised the quality of evidence thus far demonstrating the safety and effectiveness of vascular brachytherapy in treating in-stent restenosis. At the same time, however, he cautioned that the agency would thoroughly review the data before making the therapy widely available.

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel